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Abstract Background Junior doctors do most inpatient
prescribing, with a relatively high error rate, and locally had
reported finding prescribing very stressful. Objective To de-
velop an intervention to improve Foundation Year 1 (FY1)
doctors’ experience of prescribing, and evaluate their satis-
faction with the intervention and perceptions of its impact.
Methods Based on findings of a focus group and question-
naire, we developed a pocket Dose Reference Card (‘‘Dr-
Card’’) for use at the point of prescribing. This summarised
commondrugs and dosing schedules andwas distributed to all
new FY1 doctors in a London teaching trust. A post-inter-
vention questionnaire explored satisfaction and perceived
impact. Results Focus group participants (n = 12) described
feeling anxious and time pressured when prescribing; a quick
reference resource for commonly prescribed drug doses was
suggested. Responses to the exploratory questionnaire rein-
forced these findings. Following Dr-Card distribution, the
post-intervention questionnaire revealed that 29/38 (76 %)
doctors were still using it 2 months after distribution and
38/38 (100 %) would recommend ongoing production.
Conclusions FY1 doctors reported feeling stressed and time
pressured when prescribing; this was perceived to contribute
to error. A pocket card presenting common drugs and doses
was well-received, perceived to be useful, and recommended
for on-going use.
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Impact of findings on practice
• Foundation Year 1 (FY1) doctors perceived time
pressure and lack of access to information to be sources
of stress and to potentially contribute to erroneous
prescribing, suggesting these as areas for intervention.
• A locally relevant pocket reference guide developed
with input from clinical pharmacists may be useful in
improving FY1s’ experience of prescribing; ours was
widely used and recommended for ongoing use.
Introduction
Prescribing errors occur in up to 15 % ofmedication orders in
UK hospitals [1–6], comparable to international figures [7].
Interventions are therefore needed. There are many reasons
why newly qualified Foundation Year 1 (FY1) doctors are a
suitable target for such interventions. First, FY1 doctors do
most of the prescribing in the UK hospital inpatient setting
[4]. Second, while there is variation in reported junior doc-
tors’ prescribing error rates [8], FY1 doctors are reported to
have a prescribing error rate twice that of consultants [4].
Third, they are more readily accessible as a group than their
senior counterparts. Fourth, good prescribing habits learnt
early will hopefully be retained throughout a doctor’s career.
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Finally, FY1 doctors report lower confidence in their pre-
scribing skills than FY2 doctors [9], identify that lack of
knowledge of prescribing contributes to errors [10] and lo-
cally, reported finding prescribing very stressful with con-
cerns about errors. We wanted to develop and evaluate an
intervention to address these issues.
Aims
To investigate FY1s’ views on prescribing, and develop
and evaluate an intervention to improve their experience of
prescribing.
Ethical approval
This work met criteria for local audit and improvement
activities exempt from NHS ethics review, and was regis-
tered locally as an audit.
Methods
Setting
Initial development work took place across an educational or-
ganisation that provided training to 270FY1doctors regionally.
The intervention was then evaluated at a single London
teaching hospital trust in which 82 FY1s worked across three
hospital sites. In line with most UK hospitals, FY1 doctors
wrote a high proportion of inpatients’medication orders, which
were handwritten onto preformatted paper drug charts.
Developing the intervention
We first conducted a focus group with 12 FY1s to explore
FY1s’ attitudes to prescribing, identify factors perceived as
responsible for FY1 prescribing errors, and elicit potential
solutions. The discussion was recorded, transcribed and
thematically analysed.
Relevant topics identified were then explored further
using an anonymous questionnaire (electronic supplemen-
tary material 1), distributed to all 270 FY1s across the
region. Respondents were asked about prescribing confi-
dence and experiences of prescribing safety. Data were
analysed descriptively.
The intervention
The focus group (Table 1) and questionnaire results suggested
that an easily accessible reference source for local prescribing
information would be a suitable intervention. We therefore
created the Dose Reference Card (‘Dr-Card’) for commonly
prescribed drugs and doses, for use at the point of prescribing
when it was difficult to consult more detailed references. This
was designed to be a low-cost intervention to improve FY1s’
prescribing experience and support safe prescribing.
Dr-Card design
The resulting Dr-Card (Fig. 1) included the name, dose,
and route of commonly prescribed adult inpatient drugs in
our local formulary. Anti-infectives were excluded as
separate resources for these exist locally.
Insulin sliding scale and warfarin initiation protocols were
the most frequently searched terms on the prescribing guide-
lines intranet site; summaries of these were also included.
The draft contents were modified in response to sug-
gestions from specialist clinical pharmacists and FY1
representatives. The final version was approved by the
Drugs and Therapeutics Committee.
The Dr-Cards (2012 version) were printed on credit-card
sized laminated cardboard designed to be carried within
identification badge holders or pockets; they cost £108 for
100 cards.
Dr-Card distribution
The Dr-Card was distributed to FY1s during teaching
sessions in August 2012, the first month of the FY1 year.
Evaluation of the intervention
We conducted a formal post-intervention evaluation to
establish the extent to which FY1s were using the Dr-Card,
their views on its content, format and potential impact and
to identify suggestions for improvement.
We developed a questionnaire (electronic supplemen-
tary material 2) comprising open and closed questions.
A FY2 doctor and pharmacists piloted the questionnaire
and confirmed its face validity.
A pre-notification email was sent to all FY1s a week before
questionnaire distribution. Questionnaires were distributed at
FY1 teaching sessions inOctober 2012, aswewere interested in
experiences from the first months of FY1 prescribing. Ques-
tionnaires were sent to non-attendees via internal post; data
were summarised descriptively and responses expressed using
the number of respondents to each question as a denominator.
Results
Focus group
Participants described feeling anxious and under-prepared
when prescribing (Table 1) and ‘‘daunted’’ at the beginning
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Table 1 Quotes from Foundation Year 1 doctor focus group
‘‘I think it’s difficult, because on the ward round there is that time issue, it’s so quick from patient to patient, and often like they’ll say to you
prescribe this, and they’ll move on’’. Quote 1
‘‘But also I think certain things like insulin prescribing sliding scales and warfarin regimes, things that obviously they are very important,
based on each patient’s own clinical situation, there’s not really, apart from the intranet and obviously the protocols on the intranet, there’s
no quick, fast sort of source that we can refer to on the ward round. So I think if there was something that was made more readily available
to us’’. Quote 2
‘‘I use this crib sheet, this was given to me by a CT1 [core trainee year 1 doctor] or something, it’s been kept up to date, but it’s just got, it’s
A4 [paper size], it’s got all, all the antibiotics, with doses, IV [intravenous] and oral doses, anti-emetics, all your analgesia, laxatives,
urology drugs, alcoholic drugs, chlordiazepoxide, inhalers and anxiolytics’’. Quote 3
Fig. 1 The 2 sides of the the
Dr-CARD. Actual size is credit-
card sized
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of their FY1 year. Some expressed concern about getting
‘‘the simple things’’ wrong, both practically (e.g. missing
signatures) and clinically (e.g. doses). FY1s described time
pressure (quote 1) as one of the difficulties, for example not
having sufficient time to look up doses to check they were
prescribing correctly.
Participants identified that a quick reference ‘crib sheet’
would be a useful resource to enable them to look up
commonly prescribed doses quickly (quote 2). Some had
already developed their own (quote 3).
Exploratory questionnaire
Seventy-eight (29 %) of 270 FY1 doctors from the region
completed the exploratory questionnaire. One of the most
frequently reported reasons for erroneous prescribing was
time pressure (48/73 respondents to this question; 66 %);
six (8 %) stated that lack of informative resources influ-
enced erroneous prescribing. Other frequently chosen rea-
sons for erroneous prescribing were lack of knowledge of
the patient, and lack of pharmaceutical knowledge; these
will be addressed in future interventions.
The Dr-Card
A total of 77 (94 % of all 82 FY1s at ICHT) received the
Dr-Card. Forty-three of 82 (52 %) FY1s completed the
post-implementation questionnaire, of whom 41 (95 %)
had received a Dr-Card and 29/38 respondents (76 %) were
still using it at the time of the survey (Table 2). Four re-
spondents who stated they ‘‘never’’ used it had lost their
card, and one was based in paediatrics where it was not
applicable.
Thirty-seven (88 %) of 42 respondents reported being
satisfied or very satisfied with the material, colour and size
of the card; none were dissatisfied. The majority of re-
spondents (28/42; 67 %) wanted the card to be available as
both a plastic card and smartphone application.
Most (30/40; 75 %) respondents reported using the in-
dividual drugs’ dosing guidelines; 17/41 (41 %) reported
having used the insulin sliding scale and 12/40 (30 %) the
warfarin initiation protocol. One respondent reported using
the intranet guidelines instead.
Twenty (91 %) of 22 respondents thought the Dr-Card
would improve patient safety, two (9 %) disagreed. Rea-
sons given for improving safety included correct dosing,
quicker access to medication for patients and reduced stress
levels. One respondent stated that the British National
Formulary (BNF) was available and would be used instead,
and another that the Dr-Card would only improve safety if
it was kept up-to-date and used alongside the BNF.
Finally, 38 (100 %) of 38 respondents thought the Dr-
Card should be produced next year; one added that it was
particularly helpful in clinical areas where common drugs
had to be prescribed quickly. Some suggested additional
drugs and/or protocols for inclusion.
Table 2 Responses to post-implementation questionnaire
Daily Weekly Less than weekly Never Totala No answer
How often did you use your Dr-Card at first? 18 (45 %) 10 (25 %) 5 (13 %) 7 (18 %) 40 (100 %) 3
How often do you use your Dr-Card now? 6 (16 %) 17 (45 %) 6 (16 %) 9 (24 %) 38 (100 %) 5
Very satisfied Satisfied Neutral Unsatisfied Very unsatisfied Total No answer
How satisfied are you with the
material of the Dr-Card?
21 (50 %) 16 (38 %) 5 (12 %) 0 (0 %) 0 (0 %) 42 (100 %) 1
Plastic Smartphone Both No preference Total No answer
What format would you prefer
Dr-Card to be produced in?
8 (19 %) 4 (10 %) 28 (67 %) 2 (5 %) 42 (100 %) 1
Yes No Total No answer
Have you used the dosing guidelines for the individual drugs
listed on the Dr-Card?
30 (75 %) 10 (25 %) 40 (100 %) 3
Have you used the insulin sliding scale on the Dr-Card? 17 (41 %) 24 (59 %) 41 (100 %) 2
Have you used the warfarin initiation protocol on the Dr-Card? 12 (30 %) 28 (70 %) 40 (100 %) 3
Will the Dr-Card improve patient safety? 20 (91 %) 2 (9 %) 22 (100 %) 21
Should the Dr-Card be produced next year? 38 (100 %) 0 (0 %) 38 (100 %) 5
a Percentages are calculated using the number of responses to that individual question as the denominator
Int J Clin Pharm
123
Discussion
A focus group and exploratory questionnaire suggested that
a resource for use under time pressure may be helpful to FY1
doctors when prescribing. As some FY1s had already cre-
ated their own reference sources, we formalised a novel,
quick, low-cost ‘Dr-Card’, in line with local guidelines,
which was distributed to all FY1s in one trust. Although
dosing information and clinical guidelines are available on
the trust’s intranet, doctors have intermittent access to a
computer when prescribing: the Dr-Card therefore provides
an accessible summary. Its portability and local relevance
also complements the use of textbooks and tablet computers.
A post-implementation questionnaire revealed the ma-
jority of FY1 doctors viewed the Dr-Card positively, felt it
improved safety and were still using it 2 months after
distribution. All respondents thought production of the Dr-
Card should continue. Patterns of use suggest the Dr-Card
was used less over time, perhaps as FY1s gain experience.
Strengths and limitations
Strengths of our study are that we developed a low-cost,
practical intervention and evaluated its acceptability and
perceived impact. We recognise that our intervention was
based on focus group and questionnaire data from a
relatively small cohort, that the questionnaire had only a
52 % response rate and that we do not have comparative
demographic data for respondents and non-respondents.
The evaluation was limited as we were not funded to
evaluate the effect of the Dr-Card on prescribing errors.
On-going work
Based on the evaluation, we produced an updated Dr-Card
for future intakes of FY1s, presented as a more robust plastic
card and also incorporated the information into a local
smartphone application. Drugs and doses are reviewed an-
nually by clinical pharmacists, FY1s and senior doctors, to
ensure they remain aligned with local practice and relevant
guidelines. Future research should explore the effect of quick
reference guides such as the Dr-Card on prescribing errors.
Conclusions
FY1 doctors reported feeling stressed and time pressured
when prescribing; this was perceived to contribute to error.
We developed the Dr-Card as a low cost intervention to
provide key information at the point of prescribing. The
majority of FY1 doctors carried, used, and liked the Dr-
Card and thought it should be produced again. The Dr-Card
is now embedded into local practice.
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